新的抗血管生成药物阿柏西普治疗转移性结直肠癌研究进展

摘要

新生血管生成是结直肠癌发生、生长和转移的重要机制之一。阿柏西普作为血管内皮生长因子（vascular endothelial growth factor，VEGF）的可溶性诱饵受体，作用于靶点 VEGF-A、VEGF-B 和胎盘生长因子（placental growth factor，PIGF）抑制肿瘤血管的生成。最近多项研究表明阿柏西普对多种实体瘤尤其转移性结直肠癌（metastatic colorectal cancer，mCRC）有明确的抗肿瘤作用。而且美国食品药品监督管理局和欧洲药物管理局已批准阿柏西普联合5-氟尿嘧啶、亚叶酸钙和伊立替康方案（5-fluorouracil，leucovorin，irinotecan，FOLFIRI）可用于二线治疗对奥沙利铂为基础的化疗方案耐药或进展的 mCRC 患者。该文就阿柏西普抗血管生成的作用机制和在 mCRC 中的临床试验作一综述。%Angiogenesis is one of the important mechanisms for the occurrence,growth and metastasis of colorectal cancer..As a soluble decoy receptor,Ziv -aflibercept targets vascular endothelial growth factor (VEGF)-A,VEGF-B,and placental growth factor (PlGF)to inhibit tumor angiogenesis.Recently,several studies have shown that Ziv -aflibercept has explicit anti -tumor activity in a variety of solid tumors,especially advanced colorectal cancer.Food and drug administration of U.S.(FDA)and European medicines agency (EMA)approved Ziv-aflibercept in combination with 5-fluorouracil,leucovorin,and irinotecan (FOLFIRI)for patients with metastatic colorectal cancer (mCRC),that is resistant to or has progressed after an oxaliplatin-containing fluoropyrimidine-based regimen.In this review,we summarized the antiangiogenic mechanisms and clinical trials of Ziv-aflibercept for mCRC therapy.